The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | CERVINO trial results and the potential role of etentamig in multiple myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the potential role of etentamig, a BCMA-targeted bispecific antibody, in the treatment landscape for multiple myeloma following the release of CERVINO trial (NCT06158841) results. He highlights the value of randomized data for evaluating a new antibody construct and administration approach, and the potential for additional BCMA-targeted treatment options to support more personalized treatment selection. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
During this ASH meeting, we’ve seen the release of the CERVINO trial results, bringing another anti-BCMA bispecific antibody into the treatment algorithm. And I believe this is good news because the first anti-BCMA bispecific antibodies were approved based on single-arm trials, at least the original registration trials. Now having randomized data with a different construct, different affinity, different modality of administration is very welcome...
During this ASH meeting, we’ve seen the release of the CERVINO trial results, bringing another anti-BCMA bispecific antibody into the treatment algorithm. And I believe this is good news because the first anti-BCMA bispecific antibodies were approved based on single-arm trials, at least the original registration trials. Now having randomized data with a different construct, different affinity, different modality of administration is very welcome. And I personally believe that having several options, even if the target is the same, is always good news because we have to try to refine the use of these agents and probably that will bring us closer to the concept of personalized medicine.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
